Development stage candidate from Bayer Healthcare for the treatment of traumatic head injury, stroke, Parkinson's disease and Alzheimer' s disease
Summary
Acute neurodegeneration caused by stroke or trauma as well as more chronic disease resulting from Alzheimers’s disease or Parkinson’s disease has inflammatory and direct neurotoxic components. Bayer Healthcare researchers have developed a compound with anti-inflammatory and neuroprotective active resulting is therapeutic activity in models of head injury and Parkinson’s diseaseAcute neurodegeneration caused by stroke or trauma as well as more chronic disease resulting from Alzheimers’s disease or Parkinson’s disease has inflammatory and direct neurotoxic components. There is an urgent need for improved neuroprotective agents driving the development of a market expected to be worth $11.5 billion by the year 2010 (see Neuroprotection - Drugs, Markets and Companies). The transcription factors, NF-Kappa B and AP-1 are though to play an important role in both the transcription of inflammatory mediators and cell survival. Bayer Healthcare researchers have developed synthetic derivatives of the phytogenic therapeutic, Rocaglaol. The lead compound is shown here to have broad ranging anti-inflammatory and neuroprotective active resulting is therapeutic activity in models of head injury and Parkinson’s disease....[more]
Source LeadDiscovery
Featured on DailyUpdates-CNS Diseases
